Please assess the completion status of the following clinical trial:

Trial Title: Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At the time of eligibility for infusion of allodepleted T -cells patients must satisfy the criteria below:~* Patients with Fanconi anemia of all ages with severe aplasia (as evidenced by hypocellular bone marrow) who lack a suitable conventional related (i.e. 5/6 or 6/6 related) or 5/6 or 6/6 unrelated donor with at least 2 out of 3 of the following: a) ANC \< 500/mm3, b) reticulocytes \< 1% c) platelets \< 50,000/mm3~* Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow sensitivity to mitomycinC or DEB prior to stem cell transplant. Have received a related haploidentical CD34-selected peripheral blood stem cell transplant with evidence of a full or partial hematopoietic donor chimerism (\> 50%) in the peripheral blood.~Exclusion Criteria:~* Patients with a life expectancy (\< 6 weeks) limited by diseases other than FA~* Patients with active GVHD \> / = Grade II~* Patients with severe renal disease (i.e. creatinine greater than 3 X normal for age)~* Patients with severe hepatic disease (direct bilirubin greater than 3ug/dl or SGPT greater than 500ug/dl)~* Patients with a severe intercurrent infection~* Lansky scale \< 60 or Karnofsky \< 60

- Gender: ALL
- Minimum Age: None
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- CD34 selected haploidentical PBSCT (Type: EXPERIMENTAL): CD34 selected haploidentical PBSCT

Based on this trial design, predict the completion outcome and termination type (if applicable).